{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T02:00:48Z","timestamp":1771725648000,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006939","name":"Emory University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006939","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jpet.2025.103773","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:04:59Z","timestamp":1762902299000},"page":"103773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A 5\u2032-(R)-CH3-substituted 5-fluoro-2\u2032-deoxyuridine monophosphate reduces off-target toxicities while maintaining efficacy in a colorectal cancer model"],"prefix":"10.1016","volume":"393","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7802-6188","authenticated-orcid":false,"given":"Christopher M.","family":"Monaco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0439-9162","authenticated-orcid":false,"given":"Nicole","family":"Pribut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chitalu C.","family":"Musonda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie Q.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Petros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken H.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3659-0105","authenticated-orcid":false,"given":"Eric J.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis C.","family":"Liotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jpet.2025.103773_bib1","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.3390\/jcm9123889","article-title":"Metastatic colorectal cancer. First line therapy for unresectable disease","volume":"9","author":"Aparicio","year":"2020","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.jpet.2025.103773_bib2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1021\/bi00700a012","article-title":"Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate","volume":"13","author":"Santi","year":"1974","journal-title":"Biochemistry"},{"issue":"3","key":"10.1016\/j.jpet.2025.103773_bib3","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/0006-291X(74)90601-9","article-title":"Purification and amino acid analysis of an active site peptide from thymidylate synthetase containing covalently bound 5-fluoro-2\u2019-deoxyuridylate and methylenetetrahydrofolate","volume":"57","author":"Sommer","year":"1974","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.jpet.2025.103773_bib4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/FPC.0b013e32833c6107","article-title":"PharmGKB summary: fluoropyrimidine pathways","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"10.1016\/j.jpet.2025.103773_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcab032","article-title":"A novel view on an old drug, 5-fluorouracil: an unexpected RNA modifier with intriguing impact on cancer cell fate","volume":"3","author":"Chalabi-Dchar","year":"2021","journal-title":"NAR Cancer"},{"issue":"7","key":"10.1016\/j.jpet.2025.103773_bib6","first-page":"723","article-title":"Ratio of 2\u2032-deoxyadenosine-5\u2032-triphosphate\/thymidine-5\u2032-triphosphate influences the commitment of human colon carcinoma cells to thymineless death","volume":"1","author":"Houghton","year":"1995","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jpet.2025.103773_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ctrv.2016.08.002","article-title":"Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity \u2013 ready for clinical practice?","volume":"50","author":"Meulendijks","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"10.1016\/j.jpet.2025.103773_bib8","doi-asserted-by":"crossref","first-page":"13059","DOI":"10.18632\/oncotarget.14371","article-title":"Analysis of molecular mechanisms of 5-fluorouracil-induced steatosis and inflammation in vitro and in mice","volume":"8","author":"Sommer","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.jpet.2025.103773_bib9","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00280-017-3249-1","article-title":"Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia","volume":"79","author":"Nishikawa","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103773_bib10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.toxlet.2014.03.018","article-title":"A mechanistic study on the cardiotoxicity of 5-fluorouracil in vitro and clinical and occupational perspectives","volume":"227","author":"Lamberti","year":"2014","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.jpet.2025.103773_bib11","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2022.3","article-title":"Reproductive and developmental toxicities of 5-fluorouracil in model organisms and humans","volume":"24","author":"Naren","year":"2022","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.jpet.2025.103773_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107447","article-title":"5-Fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future","volume":"206","author":"Vodenkova","year":"2020","journal-title":"Pharmacol Ther"},{"issue":"2\u20133","key":"10.1016\/j.jpet.2025.103773_bib13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0163-7258(00)00048-6","article-title":"Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases","volume":"87","author":"Van Rompay","year":"2000","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jpet.2025.103773_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2005.01.003","article-title":"The 5\u2032-nucleotidases as regulators of nucleotide and drug metabolism","volume":"107","author":"Hunsucker","year":"2005","journal-title":"Pharmacol Ther"},{"issue":"23","key":"10.1016\/j.jpet.2025.103773_bib15","doi-asserted-by":"crossref","first-page":"14379","DOI":"10.1021\/acs.chemrev.6b00209","article-title":"Metabolism, biochemical actions, and chemical synthesis of anticancer nucleosides, nucleotides, and base analogs","volume":"116","author":"Shelton","year":"2016","journal-title":"Chem Rev"},{"issue":"1","key":"10.1016\/j.jpet.2025.103773_bib16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3851\/IMP1797","article-title":"Nucleotide prodrugs for HCV therapy","volume":"22","author":"Sofia","year":"2011","journal-title":"Antivir Chem Chemother"},{"issue":"23","key":"10.1016\/j.jpet.2025.103773_bib17","doi-asserted-by":"crossref","first-page":"10400","DOI":"10.1021\/acs.jmedchem.6b00523","article-title":"Nucleoside phosphate and phosphonate prodrug clinical candidates","volume":"59","author":"Thornton","year":"2016","journal-title":"J Med Chem"},{"issue":"23","key":"10.1016\/j.jpet.2025.103773_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127539","article-title":"Synthesis and biological evaluation of 5\u2032-C-methyl nucleotide prodrugs for treating HCV infections","volume":"30","author":"Dasari","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"issue":"5","key":"10.1016\/j.jpet.2025.103773_bib19","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1021\/acsptsci.2c00252","article-title":"Discovery of 5\u2032-substituted 5-fluoro-2\u2032-deoxyuridine monophosphate analogs: a novel class of thymidylate synthase inhibitors","volume":"6","author":"Dasari","year":"2023","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.jpet.2025.103773_bib20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bioorg.2013.07.004","article-title":"Synthesis, anti-thymidine phosphorylase activity and molecular docking of 5-thioxo-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-ones","volume":"50","author":"Bera","year":"2013","journal-title":"Bioorg Chem"},{"issue":"19","key":"10.1016\/j.jpet.2025.103773_bib21","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1016\/0006-2952(89)90613-8","article-title":"Evidence for acyloxymethyl esters of pyrimidine 5\u2032-deoxyribonucleotides as extracellular sources of active 5\u2032-deoxyribonucleotides in cultured cells","volume":"38","author":"Freed","year":"1989","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"10.1016\/j.jpet.2025.103773_bib22","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1128\/AAC.37.10.2247","article-title":"Metabolism and in vitro antiretroviral activities of bis(pivaloyloxymethyl) prodrugs of acyclic nucleoside phosphonates","volume":"37","author":"Srinivas","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.jpet.2025.103773_bib23","doi-asserted-by":"crossref","first-page":"6046","DOI":"10.1021\/acsomega.1c06394","article-title":"Trapping of 5-fluorodeoxyuridine monophosphate by thymidylate synthase confers resistance to 5-fluorouracil","volume":"7","author":"Kurasaka","year":"2022","journal-title":"ACS Omega"},{"issue":"6","key":"10.1016\/j.jpet.2025.103773_bib24","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1021\/acs.jmedchem.7b00734","article-title":"The ProTide prodrug technology: from the concept to the clinic","volume":"61","author":"Mehellou","year":"2018","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.jpet.2025.103773_bib25","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1177\/0960327115626583","article-title":"Mitigation of 5-fluorouracil-induced liver damage in rats by vitamin C via targeting redox-sensitive transcription factors","volume":"35","author":"Al-Asmari","year":"2016","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.jpet.2025.103773_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918780140","article-title":"5-Fluorouracil and cardiotoxicity: a review","volume":"10","author":"Sara","year":"2018","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103773_bib27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s43046-022-00117-4","article-title":"Diagnosis and management of 5-fluorouracil (5-FU)-induced acute leukoencephalopathy: lessons learnt from a single-centre case series","volume":"34","author":"Jose","year":"2022","journal-title":"J Egypt Natl Canc Inst"},{"issue":"9","key":"10.1016\/j.jpet.2025.103773_bib28","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/bjc.2012.421","article-title":"Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: a multivariate analysis","volume":"107","author":"Garg","year":"2012","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.jpet.2025.103773_bib29","first-page":"4409","article-title":"Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro","volume":"6","author":"Ikeda","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jpet.2025.103773_bib30","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211009001","article-title":"Oral drugs in the treatment of metastatic colorectal cancer","volume":"13","author":"Garc\u00eda-Alfonso","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"8","key":"10.1016\/j.jpet.2025.103773_bib31","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","article-title":"Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue","volume":"34","author":"Miwa","year":"1998","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.jpet.2025.103773_bib32","first-page":"421","article-title":"A review of the role of capecitabine in the treatment of colorectal cancer","volume":"3","author":"Comella","year":"2007","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"10.1016\/j.jpet.2025.103773_bib33","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1517\/14740338.2010.511610","article-title":"Safety of capecitabine: a review","volume":"9","author":"Mikhail","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jpet.2025.103773_bib34","author":"Draper"},{"issue":"5","key":"10.1016\/j.jpet.2025.103773_bib35","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bcp.12877","article-title":"Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment","volume":"81","author":"Derissen","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"20","key":"10.1016\/j.jpet.2025.103773_bib36","doi-asserted-by":"crossref","first-page":"7247","DOI":"10.1021\/jm200815w","article-title":"Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside","volume":"54","author":"McGuigan","year":"2011","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.jpet.2025.103773_bib37","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00280-023-04528-5","article-title":"The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agent","volume":"91","author":"Br\u00e9","year":"2023","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103773_bib38","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13046-024-03010-1","article-title":"A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301)","volume":"43","author":"Spiliopoulou","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jpet.2025.103773_bib39","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/01.COC.0000017526.55135.6D","article-title":"Severe toxicity related to the 5-fluorouracil\/leucovorin combination (the Mayo Clinic regimen): a prospective study in colorectal cancer patients","volume":"26","author":"Tsalic","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jpet.2025.103773_bib40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/2050-6511-15-47","article-title":"A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity","volume":"15","author":"Polk","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"issue":"2","key":"10.1016\/j.jpet.2025.103773_bib41","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00204-013-1118-1","article-title":"Circulating acylcarnitines as biomarkers of mitochondrial dysfunction after acetaminophen overdose in mice and humans","volume":"88","author":"McGill","year":"2014","journal-title":"Arch Toxicol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103773_bib42","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jacc.2015.10.079","article-title":"Prognostic implications of long-chain acylcarnitines in heart failure and reversibility with mechanical circulatory support","volume":"67","author":"Ahmad","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.jpet.2025.103773_bib43","doi-asserted-by":"crossref","first-page":"8430","DOI":"10.1093\/nar\/gkr563","article-title":"UNG-initiated base excision repair is the major repair route for 5-fluorouracil in DNA, but 5-fluorouracil cytotoxicity depends mainly on RNA incorporation","volume":"39","author":"Pettersen","year":"2011","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"10.1016\/j.jpet.2025.103773_bib44","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/nar\/gkl1084","article-title":"Incorporation of 5-fluorouracil into U2 snRNA blocks pseudouridylation and pre-mRNA splicing in vivo","volume":"35","author":"Zhao","year":"2007","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"10.1016\/j.jpet.2025.103773_bib45","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.chembiol.2021.06.007","article-title":"CETSA interaction proteomics define specific RNA-modification pathways as key components of fluorouracil-based cancer drug cytotoxicity","volume":"29","author":"Liang","year":"2022","journal-title":"Cell Chem Biol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103773_bib46","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41467-021-27847-8","article-title":"Alteration of ribosome function upon 5-fluorouracil treatment favors cancer cell drug-tolerance","volume":"13","author":"Therizols","year":"2022","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.jpet.2025.103773_bib47","article-title":"An RNA damage response network mediates the lethality of 5-FU in colorectal cancer","volume":"5","author":"Chen","year":"2024","journal-title":"Cell Rep Med"},{"issue":"2","key":"10.1016\/j.jpet.2025.103773_bib48","first-page":"133","article-title":"FOLFOX and FOLFIRI use in stage IV colon cancer: analysis of SEER-Medicare data","volume":"18","author":"Neugut","year":"2019","journal-title":"Clin Colorectal Cancer"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T01:33:22Z","timestamp":1771724002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525402869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0022356525402869"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103773","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A 5\u2032-(R)-CH3-substituted 5-fluoro-2\u2032-deoxyuridine monophosphate reduces off-target toxicities while maintaining efficacy in a colorectal cancer model","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103773","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103773"}}